Skip to main content
. 2024 Jan 1;14(2):699–713. doi: 10.7150/thno.90709

Figure 4.

Figure 4

Adoptive transfer of ICAM-1+CD8+ T cells enhances the systemic antitumor effect of RT. (A) Schedule of X-ray RT combined with ACT of activated CD8+ T cells from MC38 tumor-bearing ICAM-1 KO C57BL/6 donor mice or activated CD8+ T cells from MC38 or B16-F10 tumor-bearing WT C57BL/6 donor mice in ICAM-1 KO C57BL/6 mice bearing bilateral MC38 tumors. (B, C) Average tumor growth curves of primary tumors (B) and distant tumors (C) of the MC38 tumor-bearing mice after the indicated treatments as described in (A) (n = 6 per group). (D) Schedule of RT combined with ACT of WT or ICAM-1 OE CD8+ T cells in WT C57BL/6 mice bearing bilateral MC38 tumors. (E, F) Average tumor growth curves of primary tumors (E) and distant tumors (F) in the MC38 tumor-bearing mice after the indicated treatments as described in (D) (n = 5-7 per group). Data are represented as mean ± SD. P values were determined using two-way ANOVA with Tukey's multiple-comparisons test (B, C) or unpaired Student's t-test (E, F); NS, not significant (P > 0.05).